Share your innovations!

This week we announced the call for nominations for the first CIT Accelerator Awards. We will put the spotlight on innovations and processes that are working to achieve the triple aim.

Providers and other stakeholders are achieving great things across the country and we want to know about it. What projects in your organization are improving efficiency, patient outcomes and quality of care while saving time and money? Please take a few minutes to fill out the nomination and share the link with anyone else that might have a project to share.

Nominate an innovative project here.

In other news, the American Telemedicine Association is looking to launch an accreditation program this fall for primary care and urgent care. The association is seeking comment on a draft document that outlines parameters of a telehealth program. The guidelines recommend that telemedicine in primary care settings should focus on less acute conditions and for urgent care, for allergies and asthma, influenza, low back pain and upper respiratory infections.

This should go a long way in helping expand the new payment models needed to drive healthcare reform.

 

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.